Navigation Links
Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent
Date:12/16/2009

AUSTIN, Texas, Dec. 16 /PRNewswire/ -- Savara, Inc., an inhalation drug delivery company, today announced that it has closed the second tranche in its Series A financing round, exceeding the targeted total raise amount of $1.4 million.

Funds raised in the Series A round will be utilized to continue the development of the NanoCluster technology.

"We now have the runway and resources to effectively demonstrate the scalability and performance of the NanoCluster technology," said Rob Neville, CEO of Savara.

The company also announced that it has received patent allowance from the United States Patent and Trademark Office (USPTO) for its core NanoCluster technology. The patent covers its unique formulation of inhalation particles that are composed of drug nanoparticles agglomerated together (US Patent No. 11/610,986).

"Allowance on our base patent is a significant milestone in our company's history. This proprietary position is strategically important to Savara and our partners as we utilize the NanoCluster technology to improve patient health in areas of unmet need," said Neville.

About Savara's NanoCluster Technology

Particle size is critical for pulmonary drug delivery, and the ability to obtain particle sizes in the range of 1-3 microns has the potential to improve the efficacy of existing and new drug therapies. Savara's NanoCluster technology utilizes nanotechnology to formulate high performance inhalation powder without the need for novel excipients or carrier particles. Savara's NanoClusters are modeled after naturally occurring aerosols, which are highly effective in reaching the peripheral lung. These aerodynamics enable high drug concentrations in specific regions of the lung, independent of the inhalation flow rate. Savara expects that NanoCluster's unique features will enable products that are currently difficult or impossible to develop using conventional inhalation powders.

About Savara, Inc.

Savara, Inc. (www.savarapharma.com) is a drug delivery company based in Austin, Texas and a member of the Austin Technology Incubator. Savara has an exclusive license to the NanoCluster technology from the University of Kansas. Savara's NanoCluster technology is currently available for evaluation and licensing.



    Contact Information

    Media:
    Ian Stone
    Russo Partners, LLC
    (619) 528-2220
    Ian.Stone@russopartnersllc.com

    Partners & Investors:
    Rob Neville
    (512) 961-1891 x2
    rob.neville@savarapharma.com


SOURCE Savara, Inc.


'/>"/>
SOURCE Savara, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioVascular Inc. Closes $10.87 Million Series C Financing
2. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
3. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
4. Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease
5. Curemark Closes Series A Financing
6. Blue Belt Technologies, Inc. Closes Series A Financing
7. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
8. American Scientific Resources Inc. Discloses Audited Financials for 2007 and 2008
9. Keraderm Closes on $2.5 Million Investment from NewVa Capital Partners, LP
10. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
11. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 /PRNewswire/ ... Contamine, Directeur Financier Sanofi, ... santé, publie ses résultats pour le ... du Groupe, Jérôme Contamine, commente les ... et les perspectives pour le reste ...
(Date:4/29/2016)... India , April 29, 2016 ... the life science laboratory due to the growing demands ... by advance technology, contemporary automated systems are already adept ... performed by slow, tedious and manual labor. Instrumentation continues ... were not even conceivable just a few years ago. ...
(Date:4/28/2016)... April 28, 2016  While Abbott,s announced purchase ... company,s valve repair and stent business, healthcare research ... Abbott more firmly into patient monitoring.  Kalorama said ... growing device areas, with double-digit growth expected the ... Advanced Remote Patient Monitoring . Abbott ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton ... $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as ... People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent Marketing ... an exercise invention which aids in proper muscle development. , "The Gym & ... Creative Director of World Patent Marketing. "Globalization has threatened the future growth of ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
(Date:4/29/2016)... ... 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. Majid Jamali ... way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this permanent solution ... involves one or both jaw bones. This surgery is performed to correct the alignment of ...
(Date:4/29/2016)... Grants Pass, OR (PRWEB) , ... April 29, 2016 , ... ... nutritionists suggest dinner as the meal to miss. That was among the many new ... True Nutrition, on a recent Sharon Kleyne Hour® Power of Water® radio show. Bonny ...
Breaking Medicine News(10 mins):